Last reviewed · How we verify
Low dose insulin infusion
At a glance
| Generic name | Low dose insulin infusion |
|---|---|
| Sponsor | Medical University of Vienna |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Low Dose Fat-Induced Insulin Resistance (EARLY_PHASE1)
- Glucagon Resistance in Patients With MASLD and T2DM (NA)
- Maximising Time With a Normal Blood Glucose to Restore the Glucagon Response in Type 1 Diabetes (NA)
- Dopamine and Insulin in Psychosis (NA)
- Liver Glycogen and Hypoglycemia in Humans (PHASE1)
- Hybrid Closed-Loop in Diabetes Post-Kidney Transplant: A Randomized Trial (NA)
- Wharton´s Jelly Derived Mesenchymal Stromal Cell Repeated Treatment of Adult Patients Diagnosed with Type I Diabetes (PHASE1, PHASE2)
- Dexamethasone/Pancreatic Clamp P&F (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose insulin infusion CI brief — competitive landscape report
- Low dose insulin infusion updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI